MOTS-c peptide in Australia

MOTS-c is mainly studied for its effects on glucose metabolism and insulin sensitivity. The 2015 mouse study that named it reported that it prevented diet-induced obesity and age-related insulin resistance. Later rodent and cell studies looked at lung ischaemia-reperfusion injury, osteoarthritis, septic heart injury, hepatitis B infection and ovarian cancer. Reviews also discuss it as a possible exercise mimetic and in relation to ageing, because circulating levels fall with age.

The reported benefits come from animal and cell studies, not human trials. In mice, MOTS-c prevented high-fat-diet obesity and insulin resistance. In rats it reduced lung injury and mortality after ischaemia-reperfusion, and in mice it delayed cartilage degeneration in an osteoarthritis model. The human studies in these records only measure the body's own MOTS-c levels and relate them to disease.

Tasman Peptides supplies research-grade MOTS-c from Australian stock for laboratory research only. It comes as a lyophilised powder in 10 mg and 40 mg vials, and each batch is tested by HPLC. It is not sold for human or veterinary use, and it is not a registered medicine in Australia.

MOTS-c is not registered on the ARTG, and there is no TGA-approved MOTS-c product. Tasman supplies it only as a research chemical for laboratory use. It is not for human consumption, and this site does not give advice on obtaining it as a medicine.

The cost per mg depends on the vial size. The size table on this page lists the 10 mg and 40 mg vials side by side, so the per-mg figure for each can be read directly. The larger vial holds four times the peptide of the smaller one.

The difference is the amount of peptide in the vial; the material is the same. For reconstitution maths, the site uses a neutral default of 2 mL of bacteriostatic water for the 10 mg vial and 3 mL for the 40 mg vial, which changes the concentration per mL. The site's calculator works out the figures for any volume.

The abstracts in these records do not state the doses used. The founding mouse study and the later rat and mouse injury studies report outcomes but not dose, frequency or duration in their abstracts. A 2025 review compiles the doses and schedules used in preclinical metabolic studies, but the figures are not in its abstract. There are no human dosing data.

Store the dry powder at −20 °C, sealed and away from light and moisture. Once reconstituted, keep it at 2–8 °C and use it within 28 days, as is generally reported for reconstituted peptides. Avoid repeated freeze-thaw cycles of the mixed solution.

Yes, MOTS-c has a starter kit on this site, as every single-compound vial does. The kit groups the vial with the laboratory supplies usually needed to reconstitute and handle a lyophilised peptide. It is supplied for research use only.

Both are studied in relation to mitochondria, but they are different kinds of molecule. MOTS-c is a peptide the mitochondrial genome itself encodes, and it acts as a signal: it activates AMPK and moves to the nucleus to regulate genes. SS-31 is a synthetic tetrapeptide designed to sit in the inner mitochondrial membrane. The evidence for each is on its own page.